

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

NCT06619587

Status	RECRUITING
Phase	Phase 1
Sponsor	Genentech, Inc.
Enrollment	410 participants

Key Eligibility Criteria

Inclusion (2)

- Histologically documented advanced or metastatic solid tumor with KRAS G12D mutation
- Agreement to adhere to the contraception requirements described in the protocol for participants of childbearing potential and participants who produce sperm

Exclusion (3)

- Malabsorption or other condition that would interfere with enteral absorption
- Active brain metastases
- Clinically significant cardiovascular dysfunction or liver disease

Locations (36 total)

UC San Diego Moores Cancer Center, La Jolla, California, United States
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
Yale Cancer Center, New Haven, Connecticut, United States
... and 33 more locations